Dr. Lal PathLabs (LALPATHLAB) Q3 25/26 earnings summary

Executive summary

• Achieved 10.6% year-on-year revenue growth in Q3 FY26 and 10.8% for the nine-month period, driven by volume, mix enrichment, and network expansion in metro and Tier 3/4 cities.

• EBITDA before exceptional items rose 16.3% in Q3 FY26, reflecting operational efficiencies and favorable business mix.

• PAT for Q3 FY26 declined to INR 91 crore due to a one-time Labour Code cost, while 9M FY26 PAT increased 12.2% to INR 378 crore.

• SwasthFit preventive health packages contributed 26% to revenue, supporting B2C growth and market penetration.

• Launched Sovaaka, a personalized preventive healthcare platform, and expanded high-end diagnostics and AI-supported imaging.

Financial highlights

• Q3 FY26 revenue: INR 660 crore (up 10.6% YoY); nine-month revenue: INR 2,060 crore (up 10.8% YoY).

• EBITDA before exceptional items for Q3: INR 179 crore (up 16.3% YoY), margin at 27.2%.

• Q3 PAT: INR 91 crore (down from INR 98 crore YoY) due to a one-time INR 30 crore Labour Code cost; PAT margin at 13.9%.

• EPS for Q3: INR 5.4 (vs. INR 5.8 YoY); nine-month EPS: INR 22.4 (vs. INR 20 YoY).

• Net cash and cash equivalents: INR 1,411 crore as of Dec 31, 2025.

Outlook and guidance

• Management expects organic revenue growth to stabilize at 11%-12% for FY26, with potential for higher growth in future years.

• EBITDA margin guidance maintained at 27%-28% despite GST benefit pass-through and network investments.

• Focus on expanding network in underpenetrated markets, especially West and South India, and enhancing high-end test portfolio.

• Continued investment in digital platforms, technology upgrades, and preventive wellness programs to drive future growth.

• No price increases expected in the next 2-3 quarters following recent GST-related price cuts.